Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual
Shareholders' Meeting Today
Webcast to Commence at 9:15 a.m. PDT After Formal Portion of Meeting has
Concluded
MARLBOROUGH, Mass., Apr 26, 2012 (BUSINESS WIRE) -- Advanced Cell Technology,
Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine,
announced that it will webcast today's corporate presentation at 9:15 a.m. PDT,
after the formal portion of its Annual Shareholders' Meeting has concluded. Prior
to the webcast, proxy voting will be completed and the results announced to the
shareholders in attendance. The meeting is open to shareholders of record as of
March 1, 2012. After the corporate presentation, the Company will address
questions from shareholders in attendance, as well as electronically via the
webcast.
The webcast will be available live and via replay at:
*** us.meeting-stream.com
The Presentation schedule is as follows:
-- Corporate Overview- Gary Rabin, Chairman and CEO
-- Pre-clinical Programs Summary- Robert Lanza, M.D., CSO
-- RPE Clinical Program Update and FDA planning for Phase 2- Ed Mickunas, VP of
Regulatory and Clinical Affairs
-- Financial Overview- Kathy Singh, Controller
-- Strategic and Corporate Opportunities- Matt Vincent, Ph.D., Director of
Business Development
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
advancedcell.com.
============================
ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for
Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE
Cells
Institutional Review Board (IRB) Approval for Phase I/II Clinical Trial for Dry
AMD from Primary Teaching Hospital for Harvard Medical School in Ophthalmology
MARLBOROUGH, Mass., May 02, 2012 (BUSINESS WIRE) -- Advanced Cell Technology,
Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine,
announced today that Massachusetts Eye and Ear ("Mass. Eye and Ear") has received
institutional review board (IRB) approval to be a site for the company's Phase
I/II clinical trial for dry age-related macular degeneration (dry AMD), using
human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
"We are delighted to announce that Mass. Eye and Ear will participate as a site
for our clinical trial for dry AMD," said Gary Rabin, ACT's chairman and CEO.
"Dr. Dean Eliott and his team are deeply committed to finding new treatments for
preventing blindness, and we very much look forward to tapping into his expertise
and insight into the progression of macular degenerative disorders. The primary
teaching hospital for ophthalmology at Harvard Medical School, Mass. Eye and Ear
is ranked as among the top ophthalmology hospitals in the country by U.S. News &
World Report and has a reputation that is unrivaled."
The Phase I/II trial is a prospective, open-label study designed to determine the
safety and tolerability of the hESC-derived RPE cells following sub-retinal
transplantation into patients with dry AMD. The trial will ultimately enroll 12
patients, with cohorts of three patients each in an ascending dosage format.
"Dry AMD represents one of the largest unmet medical needs in ophthalmology,"
commented Dr. Dean Eliott, M.D. a full time retina surgeon, scientist and
Associate Director of the Retina Service at Mass. Eye and Ear. "We appreciate the
opportunity to get some first-hand experience with the protocol and be involved
with the international team that has been assembled around the U.S. and European
trials."
Founded in 1824, the Massachusetts Eye and Ear Infirmary is an independent
specialty hospital affiliated with Harvard Medical School.
Further information about patient eligibility for the dry AMD study is available
at clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT01344993.
About dry AMD Degenerative diseases of the retina are among the most common
causes of untreatable blindness in the world. Age-related macular degeneration
(AMD) is the leading cause of blindness in people over age 60 in the United
States, and the vast majority of cases of AMD are of the "dry" form, which is
currently untreatable.
About hESC-derived RPE Cells The retinal pigment epithelium (RPE) is a highly
specialized tissue located between the choroid and the neural retina. RPE cells
support, protect and provide nutrition for the light-sensitive photoreceptors.
Human embryonic stem cells differentiate into any cell type, including RPE cells,
and have a similar expression of RPE-specific genes compared to human RPE cells
and demonstrate the full transition from the hESC state.
About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a
biotechnology company applying cellular technology in the field of regenerative
medicine. For more information, visit advancedcell.com.
About Massachusetts Eye and Ear Located in Boston, Massachusetts, the
Massachusetts Eye and Ear Infirmary is an independent specialty hospital founded
in 1824. Mass. Eye and Ear has earned an international reputation for its
successful treatment of the most difficult diseases and conditions of the eye,
ear, nose, throat, head and neck, and for its outstanding contributions to
medical research and education. Mass. Eye and Ear is the primary teaching
hospital for Harvard Medical School in ophthalmology and otolaryngology, and
trains more than 110 residents and fellows each year in various sub-specialties,
including cornea, neuro-ophthalmology, retina, eye pathology, pediatrics,
glaucoma, ocular oncology, immunology, head and neck surgery and oncology,
pediatric otolaryngology, facial plastics, otology and oto-neurology. For more
information, visit masseyeandear.org.
SOURCE: Advanced Cell Technology, Inc.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
or
Business Development:
Advanced Cell Technology
Matthew Vincent, Ph.D., 508-756-1212 x324
mvincent@advancedcell.com |
